XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

Product Information

There were statistically significant differences in reduction of body fat mass between the study groups at the end of the study (IQP-AE-103 high dose, vs. placebo; low dose, vs. placebo and high dose vs. low dose, ). Reduction of fat-free mass was observed over time in all the three study groups; however, there were no significant differences between the study groups. Active Ingredient: Each capsule contains: Redusure™, a proprietary blend of high-swelling capacity dietary fibres.

XLS-Medical Appetite Reducer is a medical device. Only recommended for adults over 18 years of age. The use of this product by adolescents 12-18 years old is subject to the supervision of healthcare professionals. This product must be taken as a whole capsule with a full glass of water (approximately 250 ml). Do not open the capsule and avoid taking in powder form to avoid choking. Please read the enclosed product insert before use. It is recommended to drink at least 2 litres of water a day. Slight constipation could occur in case of limited liquid intake. Do not take during pregnancy or whilst breastfeeding, or if your BMI is below 18.5. Consult your healthcare professional before taking this product if you have any medical condition or if you are diabetic. Keep out of reach and sight of children. Product SpecificationFor beneficial action of fibres on gastrointestinal transit, it is recommended to drink at least 2L of water a day. Slight constipation could occur in case of limited liquid intake. If constipation persists despite adequate fluid intake, please consult your healthcare professional. As demonstrated by Zaluvida Group’s research and evidenced in InQpharm’s three bmiSMART products, efficacious, safe and easy to apply approaches to weight management do exist. They also allow adaption to individual dietary habits (such as preference for fatty foods or carbohydrate-rich diets) and can help to overcome initial hunger sensations while individuals are transitioning to a healthier diet. XLS Medical Appetite Reducer appetite suppressant and hunger control for a more efficient weight loss

In addition, a combination of dehydrated okra pod powder and inulin, the active ingredients in IQP-AE-103, has been shown to be a strong fat-binding agent in an in vitro setting simulating in vivo conditions (data not shown); it also exerts high swelling capacity and significantly enhances solution viscosity. Thus, IQP-AE-103 appears to be a promising natural agent that may help to control calorie intake, decrease absorption of dietary fat, and consequently lead to body weight reduction. XLS Medical Specialist Apetite Reducer helps the treatment and prevention of excess weight and general weight management.• Fills 30-43% of the stomach and promotes a pleasant feeling of fullness For you, we are running many services free of cost. Those services are expensive to run, requiring multiple servers to process and encode the files. The mean reduction in waist circumference was more pronounced in both IQP-AE-103 groups, compared with that in the placebo group at the end of the study. Subjects in the high-dose IQP-AE-103 arm had a mean reduction in waist circumference of 4.1 ± 3.3 cm, whereas the mean reduction in the low-dose IQP-AE-103 arm was 2.5 ± 2.4 cm, in contrast to only 0.9 ± 1.6 cm reported in the placebo group ( and versus placebo, respectively). Also, there were statistically significant differences in the percentage of subjects with reduction in hip circumference between the study groups at week 12, between high-dose IQP-AE-103 and the placebo group (91.4% vs. 54.8%; ), as well as between low-dose IQP-AE-103 and placebo groups (80% vs. 54.8%; ), however, not between low- and high-dose IQP-AE-103 groups ( ). No statistically significant differences in waist-to-hip ratio between the study groups were reported at week 12. Subjects underwent a 2-week run-in phase to assess the compliance to the study requirements and the recommended dietary regimen, before randomization for the 12-week treatment phase. Subjects were randomly allocated to either IQP-AE-103 high dose, IQP-AE-103 low dose, or the placebo group according to the randomization code provided by an independent statistician. Subjects were instructed to take two capsules of the investigational product three times daily, 15 minutes after each main meal (breakfast, lunch, and dinner), with a glass of water (250 ml). Each capsule of IQP-AE-103 high dose contained 330 mg dehydrated okra powder and 85 mg inulin, whereas low-dose capsules contained half the amount of okra powder and inulin; and placebo capsules contained standard excipients. All the capsules were identical in size and appearance. Dehydrated okra powder was obtained from whole okra pods ( Abelmoschus esculentus) that were cleaned, sliced, oven-dried at 60°C, and milled to form a fine powder. Inulin was extracted from freshly sliced chicory roots using hot water, followed by filtration and purification by discoloration and decalcification. The materials were tested for microbiological activity and contaminants, and inulin was tested for purity. The daily dosage of IQP-AE-103 was determined based on data obtained from a previous animal study that has shown efficacy in preventing weight gain and in increasing fecal excretion (data not shown). Considering the mode of action of the product, that is, reducing dietary fat absorption, the daily dosage was divided into 3 equal doses to be consumed after 3 main meals.

Indications

Figure 2: Litramine 14-week placebo-controlled, randomised, double-blind clinical trial results Weight loss through digestive enzyme inhibition This research confirms Redusure's role in appetite reduction by promoting pleasant feelings of fullness when taken before meals,' stated Holly Tully, VP of Marketing, InQpharm NA. 'The study also reveals just how effective these appetite-reducing properties are in helping individuals lose weight at a consistent, healthy rate.' There are three ways to upload your file: drag & drop, browse your hard drive or upload a PDF file from the cloud. shoppingListJS = new ShoppingListJS({storeId: '11352',catalogId: '28501',langId: '-1'}, {id: '2019433', name: 'XLS-Medical Hunger Buddy - 40 Capsules', image: '', type: 'ItemBean', components: {}, skus: []}, {}, "shoppingListJS"); Hunger Buddy is clinically proven to promote significant weight loss through a reduced food intake. It is particularly suitable for those who constantly have a big appetite and cannot control portion size. Hunger Buddy is a certified medical device product for the treatment and

All XLS-Medical products carry the CE logo, indicating they have been assessed to meet high safety, health, and environmental protection requirements Missing a deadline could result in your trademark becoming abandoned. You can get the free status update report for this canadian trademark. In summary, the study results provide the first promising evidence that the intake of IQP-AE-103 causes weight loss in overweight and moderately obese subjects in conjunction with a mild hypocaloric diet. The 12-week treatment with IQP-AE-103 also showed very good tolerability. Taken together, IQP-AE-103 can be considered as a safe and effective strategy in fighting obesity with potential benefits in maintaining healthy blood lipids. Data Availability For the treatment and prevention of excess weight. Fight food cravings & cut portion sizes. 94% experinced a feeling of fullness.Plants have always been a good source of new potential and natural therapies for illnesses, including body weight management products. Litramine®, a natural fibre complex derived from Opuntia ficus-indica, enriched with soluble fibres from Acacia sp., has been shown in a number of clinical trials to safely and effectively reduce and maintain weight loss [ 17– 20]. Litramine® has been demonstrated to reduce dietary fat absorption and increase fecal fat excretion, resulting in lower calorie absorption from diet, which leads to weight loss [ 20, 21]. Another finding of this study is that besides weight loss, IQP-AE-103 showed beneficial effects on lipid metabolism. A significantly higher proportion of subjects in the high-dose IQP-AE-103 group experienced a reduction in triglyceride levels at the end of the study compared with placebo. In subjects with higher baseline total cholesterol levels (>6.2 mmol/L), high dose of IQP-AE-103 was shown to significantly reduce total cholesterol and LDL-cholesterol (pre-post change). Therefore, current outcome suggests that long-term treatment with IQP-AE-103 could be beneficial for subjects with elevated blood lipid levels in reducing the risk of cardiovascular disease. bmiSMART is the first weight management brand to introduce oral weight management treatments from InQpharm, a Zaluvida Group, which are based on continuous biotech innovations and research. Do not take Hunger Buddy during pregnancy or whilst breastfeeding, or if your BMI (Body Mass Index) is below 18.5. It is recommended that you calculate your BMI before and during use.